Stock A323990 VAXCELL-BIO THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vaxcell-Bio Therapeutics Co., Ltd.

Equities

A323990

KR7323990002

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-06-25 EDT 		5-day change 1st Jan Change
15,140 KRW -1.17% Intraday chart for Vaxcell-Bio Therapeutics Co., Ltd. -5.90% -32.56%
2023 Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
2021 Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 2,517,196 660,678 519,865 516,197
Enterprise Value (EV) 1 2,498,632 633,590 499,579 466,512
P/E ratio -238 x -115 x -63.5 x -42.9 x
Yield - - - -
Capitalization / Revenue - - - 37,614,610,750 x
EV / Revenue - - - 33,994,130,725 x
EV / EBITDA -614 x -112 x -63.2 x -42 x
EV / FCF -1,090,436,166 x -98,474,937 x -107,428,625 x -66,035,574 x
FCF Yield -0% -0% -0% -0%
Price to Book 36.3 x 22 x 22.3 x 6.17 x
Nbr of stocks (in thousands) 18,055 18,268 18,268 22,993
Reference price 2 139,417 36,167 28,458 22,450
Announcement Date 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - 13.72
EBITDA 1 -2,392 -3,826 -4,070 -5,647 -7,901 -11,107
EBIT 1 -2,422 -4,011 -4,255 -5,904 -8,213 -11,507
Operating Margin - - - - - -83,851.26%
Earnings before Tax (EBT) 1 -6,448 -1,254 -3,984 -4,763 -6,825 -10,274
Net income 1 -6,448 -1,254 -3,984 -4,763 -6,825 -10,274
Net margin - - - - - -74,865.84%
EPS 2 -1,819 -286.0 -585.5 -315.2 -448.3 -523.8
Free Cash Flow - -15,205 -2,291 -6,434 -4,650 -7,065
FCF margin - - - - - -51,478.51%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 12/31/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 2,541 7,611 18,563 27,088 20,287 49,685
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - -15,205 -2,291 -6,434 -4,650 -7,065
ROE (net income / shareholders' equity) - -987% -18.2% -14.7% -25.6% -19.2%
ROA (Net income/ Total Assets) - -22.5% -11.7% -11.1% -18.5% -13.2%
Assets 1 - 5,575 34,108 43,093 36,858 77,959
Book Value Per Share 2 -3,440 2,069 3,840 1,647 1,277 3,636
Cash Flow per Share 2 1,254 929.0 1,097 126.0 21.30 394.0
Capex 1 465 822 26.9 2,124 167 166
Capex / Sales - - - - - 1,208.17%
Announcement Date 12/31/19 2/29/20 3/1/21 3/1/22 3/1/23 2/29/24
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VAXCELL-BIO THERAPEUTICS CO., LTD. Stock Vaxcell-Bio Therapeutics Co., Ltd.
-32.56% 253M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.38% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.38% 116B
ARGENX SE Stock argenx SE
+22.18% 27.03B
BIONTECH SE Stock BioNTech SE
-21.23% 20.36B
GENMAB A/S Stock Genmab A/S
-16.89% 16.43B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.28% 15.91B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.6B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+61.54% 14.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.38% 13.59B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. A323990 Stock
  4. Financials Vaxcell-Bio Therapeutics Co., Ltd.